Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

The following is a summary of “Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.